| Index | — | P/E | 23.66 | EPS (ttm) | 3.39 | Insider Own | 1.14% | Shs Outstand | 54.93M | Perf Week | -0.51% |
| Market Cap | 4.41B | Forward P/E | 17.13 | EPS next Y | 4.68 | Insider Trans | -2.09% | Shs Float | 54.84M | Perf Month | 6.85% |
| Enterprise Value | 4.23B | PEG | 1.21 | EPS next Q | 1.06 | Short Float | 11.31% | Perf Quarter | -6.00% | ||
| Income | 189.00M | P/S | 2.99 | EPS this Y | 12.81% | Short Ratio | 9.55 | Perf Half Y | 35.79% | ||
| Sales | 1.47B | P/B | 3.33 | EPS next Y | 7.51% | ROA | 7.14% | Short Interest | 6.20M | Perf YTD | 30.36% |
| Book/sh | 24.12 | P/C | 8.52 | EPS next 5Y | 19.59% | ROE | 15.41% | 52W High | 85.76 -6.47% | Perf Year | 51.94% |
| Cash/sh | 9.41 | P/FCF | 29.77 | EPS past 3/5Y | — | ROIC | 10.19% | 52W Low | 48.82 64.30% | Perf 3Y | 70.22% |
| Dividend Est. | — | EV/EBITDA | 19.51 | Sales past 3/5Y | 10.74% 8.25% | Gross Margin | 68.18% | Volatility | 2.98% 2.82% | Perf 5Y | -0.51% |
| Dividend TTM | — | EV/Sales | 2.88 | EPS Y/Y TTM | — | Oper. Margin | 13.48% | ATR (14) | 2.32 | Perf 10Y | 42.14% |
| Dividend Ex-Date | — | Quick Ratio | 1.21 | Sales Y/Y TTM | 12.37% | Profit Margin | 12.82% | RSI (14) | 55.13 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.45 | EPS Q/Q | 20.00% | SMA20 | 2.21% | Beta | 0.91 | Target Price | 93.33 |
| Payout | 0.00% | Debt/Eq | 0.26 | Sales Q/Q | 10.76% | SMA50 | 2.15% | Rel Volume | 0.95 | Prev Close | 78.97 |
| Employees | 3,300 | LT Debt/Eq | 0.26 | Earnings | Nov 04 | SMA200 | 9.90% | Avg Volume | 635.15K | Price | 80.21 |
| IPO Date | Oct 19, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 15.12% 2.65% | Net Debt/EBITDA | -0.80 | Volume | 605,522 | Change | 1.57% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-06-26 | Initiated | Barclays | Overweight | $76 → $105 |
| Sep-02-26 | Reiterated | Piper Sandler | Overweight | $85 → $90 |
| Aug-05-26 | Reiterated | Stifel Nicolaus | Buy | $80 → $85 |
| Aug-05-26 | Reiterated | Needham | Buy | $81 → $93 |
| Jul-15-26 | Reiterated | Mizuho | Outperform | $90 → $95 |
| Jun-22-26 | Reiterated | Keybanc | Overweight | $81 → $92 |
| May-07-26 | Reiterated | Barclays | Equal Weight | $67 → $76 |
| May-07-26 | Reiterated | Mizuho | Outperform | $72 → $90 |
| Feb-25-26 | Reiterated | Stifel Nicolaus | Buy | $70 → $80 |
| Feb-25-26 | Reiterated | Needham | Buy | $88 → $81 |
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,472 | 1,388 | 1,253 | 1,154 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 468 | 448 | 383 | 382 | — | — | — | — | — | |
| Gross Profit | 1,004 | 940 | 871 | 771 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 584 | 549 | 526 | 518 | — | — | — | — | — | |
| Research and Development | 204 | 186 | 183 | 194 | — | — | — | — | — | |
| Other Operating Expense | 17 | 6 | 33 | 128 | — | — | — | — | — | |
| Operating Income | 199 | 199 | 129 | -68 | — | — | — | — | — | |
| Interest Expense | 46 | 49 | 63 | 59 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -45 | -371 | 22 | 46 | — | — | — | — | — | |
| Net Income Before Taxes | 108 | -221 | 88 | -81 | — | — | — | — | — | |
| Income Taxes | -82 | 22 | 25 | -99 | — | — | — | — | — | |
| Consolidated Net Income | 189 | -242 | 63 | 18 | — | — | — | — | — | |
| Net Income From Continuing Operations | 189 | -242 | 63 | 18 | — | — | — | — | — | |
| Net Income | 189 | -242 | 63 | 18 | — | — | — | — | — | |
| EPS (Recurring) | 3.45 | -4.45 | 1.17 | 0.33 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.45 | -4.45 | 1.17 | 0.33 | — | — | — | — | — | |
| EPS (Diluted) | 3.39 | -4.45 | 1.16 | 0.32 | — | — | — | — | — | |
| EBITDA | 217 | -129 | 203 | 38 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 23.66 | — | 39.92 | 161.69 | — | — | — | — | — | |
| Price To Sales Ratio | 3.00 | 2.44 | 2.00 | 2.42 | — | — | — | — | — | |
| Gross Margin | 68.21 | 67.72 | 69.51 | 66.81 | — | — | — | — | — | |
| Operating Margin | 13.52 | 14.34 | 10.30 | -5.89 | — | — | — | — | — | |
| Net Margin | 12.84 | -17.44 | 5.03 | 1.56 | — | — | — | — | — | |
| Shares Outstanding | 55 | 55 | 54 | 54 | — | — | — | — | — | |
| Market Capitalization | 4,412 | 3,384 | 2,501 | 2,794 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bianchi Francesco | Director | Sep 10 '26 | Sale | 78.01 | 3,500 | 273,032 | 4,434 | Sep 14 |
| Story Brooke | Director | Sep 04 '26 | Sale | 81.42 | 2,300 | 187,270 | 7,488 | Sep 08 |
| Bianchi Francesco | Director | Aug 31 '26 | Sale | 79.72 | 1,650 | 131,538 | 7,934 | Sep 02 |
| Tezel Ahmet | Chief Innovation Officer | Aug 11 '26 | Option Exercise | 52.68 | 12,692 | 668,615 | 18,782 | Aug 13 |
| Tezel Ahmet | Chief Innovation Officer | Aug 11 '26 | Sale | 77.74 | 2,675 | 207,942 | 6,090 | Aug 13 |
| WILVER PETER M | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 10,780 | Jun 17 |
| SCHERMERHORN TODD C | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 13,105 | Jun 17 |
| Bianchi Francesco | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 11,270 | Jun 17 |
| Bianchi Francesco | Director | Jun 15 '26 | Sale | 80.19 | 1,200 | 96,228 | 9,584 | Jun 17 |
| PODLOGAR SUSAN M | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 6,128 | Jun 17 |
| Barry James Christopher | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 8,404 | Jun 17 |
| Tezel Ahmet | Chief Innovation Officer | Jun 15 '26 | Option Exercise | 0.00 | 2,965 | 0 | 7,122 | Jun 17 |
| KOZY WILLIAM A | Director | Jun 15 '26 | Option Exercise | 0.00 | 5,681 | 0 | 38,248 | Jun 17 |
| Enxing Seng Stacy | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 15,793 | Jun 17 |
| Story Brooke | Director | Jun 15 '26 | Option Exercise | 0.00 | 4,042 | 0 | 10,274 | Jun 17 |